Phase I/II Study of Oncolytic HSV in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
نویسندگان
چکیده
Authors' A Marsden H London Sc Inc, Wobur Note: Supp Research O This study Orlando, Fl Correspon The Institut United Kin Kevin.Harri
منابع مشابه
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.
PURPOSE This study sought to define the recommended dose of JS1/34.5-/47-/GM-CSF, an oncolytic herpes simplex type-1 virus (HSV-1) encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF), for future studies in combination with chemoradiotherapy in patients with squamous cell cancer of the head and neck (SCCHN). EXPERIMENTAL DESIGN Patients with stage III/IVA/IVB SCCHN receive...
متن کاملHyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
BACKGROUND The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (HFRCB) combined with simultaneous chemotherapy with weekly cisplatin (CDDP) in locally advanced inoperable head and neck cancer. METHODS From August 1999 to December 2002, 37 patients (median age, 59 years) with Union Internationale Contre le Cancer stage III (n = ...
متن کاملنقش سلکوکسیب همراه با کمورادیاسیون در کاهش موکوزیت و سایر عوارض حاد بیماران با کانسرهای پیشرفته سر و گردن
Background: Chemo-radiotherapy-induced oral mucositis represents a therapeutic challenge frequently encountered in cancer patients. This side effect causes significant morbidity and may delay or interruption of treatment plan, cyclo-oxygenase 2 (COX2) is an inducible enzyme primarily expressed in inflamed and tumoral tissues. COX-2 inhibitors have shown promise to reduce chemoradiation induce t...
متن کاملCancer Therapy: Clinical A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck
Purpose: Erlotinib, an orally active selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, has synergistic activity with radiation and with cisplatin. The EGFR is overexpressed in the majority of head and neck cancers. The primary objective of this phase I study was to determine the maximum-tolerated dose (MTD) of erlotinib in combination with low-dose daily cispla...
متن کاملCONSOLIDATION TREATMENT WITH INTRAPERITONEAL CISPLATIN IN EPITHELIAL OVARIAN CANCER FOLLOWING NEGATIVE SURGICAL ASSESSMENT
Objective: The goal of this study is to evaluate the efficacy of intraperitoneal (JP) cisplatin as consolidation treatment, in epithelial ovarian cancer patients with pathologically negative surgical reassessment, following first-line platinum-based chemotherapy. Methods: This study included 22 patients with FIGO stage (IIc- IV) epithelial ovarian cancer (EOC) which had no evidence of disea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010